Key Highlights

  • Reckitt Benckiser Group plc (LSE:RKT) reported third-quarter Core Reckitt like-for-like net Revenue growth of 3.3% to £2,690 million.
  • Full-year Core Reckitt like-for-like growth guidance was trimmed to 3.5% to 4.5%, from 4% to 5%.
  • Emerging Markets grew 8.0% like for like, or 9.8% excluding the Russia hygiene business.
  • Group IFRS net revenue fell 6.9% in the quarter, mainly reflecting the sale of Essential Home at the end of 2025.

Why Reckitt Is in Focus Today

Reckitt Benckiser Group plc (LSE:RKT), the maker of Dettol, Durex, Finish, Lysol and Strepsils, is in focus on the FTSE 100 as investors assess the consumer staples sector after a busy reporting season. Reckitt published its third-quarter update on 27 October 2026, trimming its full-year growth range. Since then, peers have reported mixed results: Unilever beat expectations, while Haleon cut guidance and its shares fell sharply. On Wednesday, 4 November, the FTSE 100 rose 1.8% after the US midterm elections.

Reckitt shares had fallen around 10% this year before the update, reflecting concern about growth in Europe and North America and the impact of a weaker cold and flu season on its health brands.

Third-Quarter Update in Detail

Core Reckitt, which excludes the Mead Johnson nutrition Business and the divested Essential Home unit, delivered like-for-like net revenue growth of 3.3% to £2,690 million in the third quarter. Excluding the Russia hygiene business, which is being wound down, core growth was 3.9%. Group like-for-like growth was 3.2%, with net revenue of £3,362 million. On an IFRS basis, group net revenue fell 6.9% because the prior-year figures included £479 million of revenue from Essential Home.

Emerging Markets were again the standout region, with like-for-like growth of 8.0%, or 9.8% excluding Russia hygiene. Chief executive Kris Licht said the business was driving good underlying performance despite a challenging consumer environment and entered the fourth quarter with momentum.

Revised Guidance

Reckitt now expects Core Reckitt like-for-like net revenue growth of 3.5% to 4.5% for 2026, down from its previous 4% to 5% range, which is also its medium-term target. Emerging Markets are expected to deliver high single-digit growth. The company said its Fuel for Growth cost programme should largely offset stranded costs from the Essential Home sale, and it reiterated its ambition for long-term sustainable Earnings Per Share growth.

Portfolio Reshaping

Reckitt has been simplifying its portfolio to focus on higher-growth health, hygiene and intimate wellness brands. It sold Essential Home, which included brands such as Air Wick and Cillit Bang, to Private Equity group Advent, completing the deal on 31 December 2025, and returned about £1.6 billion to shareholders through a Special Dividend in February 2026. It is also working on the future of Mead Johnson, its infant formula business.

Market Context on 4 November

Consumer goods companies face higher input and energy costs linked to the Middle East conflict, and many have raised prices. The fall in Brent Crude below $100 a barrel on Wednesday could ease some cost pressures over time. A weaker dollar affects Reckitt's reported sterling results because a large share of sales are in dollars and emerging market currencies. The cold and flu season is a key swing Factor for health brands such as Mucinex and Strepsils.

Power Brands and Innovation

Reckitt focuses its Investment on a group of power brands, including Dettol, Lysol, Durex, Finish, Vanish, Nurofen, Strepsils, Mucinex and Gaviscon. These brands occupy leading positions in their categories and command premium prices. Innovation, such as new formats and product extensions, and Marketing support are central to driving growth. In emerging markets, the company has used digital channels and livestream selling in China to reach consumers. Management believes this focused portfolio, combined with cost savings, will allow Reckitt to return to its medium-term growth target of 4% to 5% while improving margins over time.

Risks to Consider

Risks include weaker consumer Demand in developed markets, cost inflation, currency movements, competition from private label products, litigation related to infant formula in the United States and execution risk in portfolio changes. A soft cold and flu season would weigh on fourth-quarter health sales.

What Investors Are Watching Next

Investors will watch fourth-quarter trading, particularly cold and flu demand in North America and Europe, and the full-year results in early March 2027, which will set guidance for 2027. Updates on Mead Johnson and further cost savings will also matter for Reckitt Benckiser Group plc (LSE:RKT).